ERA Banner
Download Add to Cart Share
More Like This
  • http://hdl.handle.net/10402/era.25329
  • Characterization of Phosphoglycerate Kinase Expressed on the Surface of Group B Streptococcus
  • Boone, Tyler J
  • English
  • Group B Streptococcus
    Phosphoglycerate Kinase
    Glycolytic
  • Jan 30, 2012 3:28 PM
  • Thesis
  • English
  • Adobe PDF
  • 3700136 bytes
  • Group B streptococcus (GBS) is a major cause of invasive disease in the neonatal and adult populations. To mediate invasive disease, GBS encodes a variety of surface expressed and secreted components. One surface expressed protein that may contribute to GBS virulence is phosphoglycerate kinase (PGK; a glycolytic enzyme). Glycolytic enzymes have been identified on the surface of many Gram positive bacteria, despite the absence of any known secretion or surface attachment signal. My results demonstrate that the SecA2 locus, in particular the Srr1 fimbrial protein, is required for transport of PGK across the GBS membrane. Once across the bacterial membrane, PGK becomes attached to the bacterial surface through interaction with lipoteichoic acid as well as a second ligand that also requires Srr1 for expression. While the surface localization of PGK suggests it may play a role in GBS virulence, confirming their role in virulence has been hampered by its role in glycolysis. Due to the essential cytoplasmic role of PGK in metabolism, traditional knock-out mutagenesis is not possible to determine its function on the bacterial surface. My results demonstrate that GBS-PGK may contribute to GBS virulence through its ability to bind to actin, fibrin, fibrinogen, fibronectin and plasminogen. Site directed mutagenesis, preventing interaction with host proteins without affecting the glycolytic activity, has previously been used to demonstrate a role for the glycolytic enzymes -enolase and glyceraldehyde-3-phosphate dehydrogenase in virulence. Using truncation followed by peptide mapping experiments the actin and plasminogen binding sites of GBS-PGK were located to the amino acids 126-134 and amino acids 302-306. Using site directed mutagenesis, targeting these two locations within the GBS-PGK molecule, I have reduced the actin and plasminogen binding by GBS-PGK without affecting the glycolytic activity. In conclusion, the research presented in this thesis identifies the pathway utilized by GBS-PGK to become surface expressed, identifies potential virulence functions of surface expressed GBS-PGK and identifies mutations within the pgk gene that could prevent these virulence functions without affecting glycolysis. This work contributes to our understanding of surface expressed glycolytic enzymes and should facilitate future research determining the function of surface expressed GBS-PGK.
  • Verani JR, Schrag SJ. Group B streptococcal disease in infants: Progress in prevention and continued challenges. Clin Perinatol. 2010 Jun;37(2):375-92.
    Rubens CE, Smith S, Hulse M, Chi EY, van Belle G. Respiratory epithelial cell invasion by group B streptococci. Infect Immun. 1992 Dec;60(12):5157-63.
    Pancholi V, Chhatwal GS. Housekeeping enzymes as virulence factors for pathogens. Int J Med Microbiol. 2003 Dec;293(6):391-401.
    Doran KS, Nizet V. Molecular pathogenesis of neonatal group B streptococcal infection: No longer in its infancy. Mol Microbiol. 2004 Oct;54(1):23-31.
    Soriani M, Santi I, Taddei A, Rappuoli R, Grandi G, Telford JL. Group B streptococcus crosses human epithelial cells by a paracellular route. J Infect Dis. 2006 Jan 15;193(2):241-50.
    Bergmann S, Rohde M, Chhatwal GS, Hammerschmidt S. Alpha-enolase of streptococcus pneumoniae is a plasmin(ogen)-binding protein displayed on the bacterial cell surface. Mol Microbiol. 2001 Jun;40(6):1273-87.
    Boone TJ, Burnham CA, Tyrrell GJ. Binding of group B streptococcal phosphoglycerate kinase to plasminogen and actin. Microb Pathog. 2011 Jun 28.
  • Doctoral
  • Doctor of Philosophy
  • Medical Sciences- Laboratory Medicine and Pathology
  • Spring 2012
  • Gregory Tyrrell (Laboratory Medicine and Pathology)
  • Jeffrey Fuller (Laboratory Medicine and Pathology, University of Alberta)
    Brenda Leskiw (Biological Sciences, University of Alberta)
    Markus Stein (Health Sciences, Albany College of Pharmacy and Health Sciences)
    Stefan Pukatzki (Medical Microbiology and Immunology, University of Alberta)
    Song Lee (Microbiology and Immunology, Dalhousie University)